NASDAQ Stock Market Pre-Market Gainers and Losers

Strategic Insights -

The NASDAQ Stock Market kicked off the trading session with significant gains in several companies, while others faced setbacks. Oncothyreon, Affymetrix, USA Technologies, BroadSoft, and MannKind were among the leading gainers, with Oncothyreon's stock jumping 10.74 percent to $4.95. Affymetrix reported a major milestone with the U.S. Food and Drug Administration's clearance of its GeneChip Microarray Instrument System. BroadSoft raised its earnings guidance for the second quarter and full year 2011, citing strong revenue growth. Meanwhile, Zoran Corp., GTX, Auxilium Pharmaceuticals, ARM Holdings, and Lionbridge Technologies were among the leading losers, with Zoran Corp.'s stock plummeting 13.36 percent to $8.30.

Key Takeaways:

  • Oncothyreon's stock jumped 10.74 percent to $4.95 in the pre-market trading, driven by a widening loss for the first quarter of $7.1 million, or $0.24 per share.
  • Affymetrix reported a significant milestone with the U.S. Food and Drug Administration's clearance of its GeneChip Microarray Instrument System, expanding its offerings for diagnostic test development and companion diagnostics.
  • BroadSoft raised its earnings guidance for the second quarter and full year 2011, citing strong revenue growth and increased cash flow from operations.
  • USA Technologies' stock grew 7.02 percent to $2.59 in the pre-market trading, driven by a 10.28 percent increase in revenue for the first quarter.
  • MannKind Corp. (MNKD) stock increased 5.75 percent to $4.60 in the pre-market trading, ahead of its first quarter earnings release, which is expected to show a loss of $0.29 per share.
  • Zoran Corp. (ZRAN) stock plunged 13.36 percent to $8.30 in the pre-market trading, driven by a widening loss for the first quarter of $30.4 million, or $0.62 per share.
  • GTX Inc. (GTXI) stock fell 7.22 percent to $5.01 in the pre-market trading, driven by a loss for the first quarter of $2.6 million, or $0.05 per share.
  • Auxilium Pharmaceuticals' stock slid 2.05 percent to $22.96 in the pre-market trading, driven by a widening loss for the first quarter of $11.8 million, or $0.25 per share.

Statistics:

  • Oncothyreon's revenue grew to $145,000 from $5,000 for the first quarter.
  • Affymetrix's Gene Profiling Reagents offer unparalleled convenience by simplifying assay workflow, decreasing hands-on time, and reducing quality control testing compared to research-use-only-produced products.
  • BroadSoft raised its adjusted earnings guidance for the second quarter and full year 2011 to $0.09 to $0.11 per share and $0.67 to $0.77 per share, respectively.
  • MannKind Corp. expects a loss of $0.29 per share for the first quarter, compared to a loss of $0.40 per share last year.
  • Zoran Corp.'s revenue fell to $84.9 million from $90.5 million for the first quarter.
  • GTX Inc.'s loss for the first quarter was $2.6 million, or $0.05 per share, compared to a profit of $44.34 million, or $1.22 per share last year.
  • Auxilium Pharmaceuticals' revenue rose to $58.4 million from $45.5 million for the first quarter.

Sources:

  • Oncothyreon Inc. (ONTY)
  • Affymetrix Inc. (AFFX)
  • USA Technologies Inc. (USAT)
  • BroadSoft, Inc. (BSFT)
  • MannKind Corp. (MNKD)
  • Zoran Corp. (ZRAN)
  • GTX Inc. (GTXI)
  • Auxilium Pharmaceuticals Inc. (AUXL)
  • ARM Holdings plc (ARMH)
  • Lionbridge Technologies Inc. (LIOX)